Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlyin...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477487/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527511340548096 |
|---|---|
| author | Anas Abunada Madiha Shah Ateesh Kumar Syeda Lamiya Mir Dinesh Kumar Saboor Ahmed Muhammad Tanzeel Vikash Kumar Aashish Meghjiani Muhammad Basit Ali Siddiqui Govinda Khatri Aneesh Rai Fnu Deepak Ayush Kumar |
| author_facet | Anas Abunada Madiha Shah Ateesh Kumar Syeda Lamiya Mir Dinesh Kumar Saboor Ahmed Muhammad Tanzeel Vikash Kumar Aashish Meghjiani Muhammad Basit Ali Siddiqui Govinda Khatri Aneesh Rai Fnu Deepak Ayush Kumar |
| author_sort | Anas Abunada |
| collection | DOAJ |
| description | IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies. Cardiac myosin inhibitors such as mavacamten and aficamten present potential new treatment options.MethodsA meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA guidelines. Studies comparing cardiac myosin inhibitors with placebo were reviewed, and outcomes related to NYHA functional class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), LVOT gradients, and left ventricular ejection fraction (LVEF) were analyzed.ResultsSix RCTs involving 826 participants demonstrated that mavacamten and aficamten significantly improved NYHA functional class and KCCQ-CSS scores. The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) was similar between the treatment and control groups, indicating a comparable safety profile.ConclusionCardiac myosin inhibitors are effective in improving cardiac function and reducing LVOT obstruction in HCM patients. They offer a promising alternative to current treatments, with a safety profile comparable to placebo. Further research is needed to confirm long-term benefits. |
| format | Article |
| id | doaj-art-5d16e737ac78474c8d4aa9901f9ced63 |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-5d16e737ac78474c8d4aa9901f9ced632025-01-15T14:05:13ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-01-011110.3389/fcvm.2024.14774871477487Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trialsAnas Abunada0Madiha Shah1Ateesh Kumar2Syeda Lamiya Mir3Dinesh Kumar4Saboor Ahmed5Muhammad Tanzeel6Vikash Kumar7Aashish Meghjiani8Muhammad Basit Ali Siddiqui9Govinda Khatri10Aneesh Rai11Fnu Deepak12Ayush Kumar13Department of Cardiology, Liaquat University of Medical & Health Sciences, Jamshoro, PakistanDepartment of Cardiology, Liaquat University of Medical & Health Sciences, Jamshoro, PakistanDow Medical College, Dow University of Health Sciences, Karachi, PakistanDow Medical College, Dow University of Health Sciences, Karachi, PakistanDepartment of Cardiology, Liaquat University of Medical & Health Sciences, Jamshoro, PakistanDow Medical College, Dow University of Health Sciences, Karachi, PakistanDepartment of Cardiology, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, PakistanDepartment of Cardiology, Jinnah Sindh Medical University, Karachi, PakistanDow Medical College, Dow University of Health Sciences, Karachi, PakistanDow Medical College, Dow University of Health Sciences, Karachi, PakistanDow Medical College, Dow University of Health Sciences, Karachi, PakistanDow Medical College, Dow University of Health Sciences, Karachi, PakistanDepartment of Cardiology, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, PakistanDepartment of Cardiology, Vayodha Hospitals, Kathmandu, NepalIntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies. Cardiac myosin inhibitors such as mavacamten and aficamten present potential new treatment options.MethodsA meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA guidelines. Studies comparing cardiac myosin inhibitors with placebo were reviewed, and outcomes related to NYHA functional class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), LVOT gradients, and left ventricular ejection fraction (LVEF) were analyzed.ResultsSix RCTs involving 826 participants demonstrated that mavacamten and aficamten significantly improved NYHA functional class and KCCQ-CSS scores. The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) was similar between the treatment and control groups, indicating a comparable safety profile.ConclusionCardiac myosin inhibitors are effective in improving cardiac function and reducing LVOT obstruction in HCM patients. They offer a promising alternative to current treatments, with a safety profile comparable to placebo. Further research is needed to confirm long-term benefits.https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477487/fullhypertrophic cardiomyopathycardiac myosin inhibitorsmavacamtenaficamtenLVOT obstruction |
| spellingShingle | Anas Abunada Madiha Shah Ateesh Kumar Syeda Lamiya Mir Dinesh Kumar Saboor Ahmed Muhammad Tanzeel Vikash Kumar Aashish Meghjiani Muhammad Basit Ali Siddiqui Govinda Khatri Aneesh Rai Fnu Deepak Ayush Kumar Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials Frontiers in Cardiovascular Medicine hypertrophic cardiomyopathy cardiac myosin inhibitors mavacamten aficamten LVOT obstruction |
| title | Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy a meta analysis of randomized controlled trials |
| topic | hypertrophic cardiomyopathy cardiac myosin inhibitors mavacamten aficamten LVOT obstruction |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477487/full |
| work_keys_str_mv | AT anasabunada efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT madihashah efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT ateeshkumar efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT syedalamiyamir efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT dineshkumar efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT saboorahmed efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT muhammadtanzeel efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT vikashkumar efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT aashishmeghjiani efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT muhammadbasitalisiddiqui efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT govindakhatri efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT aneeshrai efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT fnudeepak efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials AT ayushkumar efficacyandsafetyofcardiacmyosininhibitorsforsymptomatichypertrophiccardiomyopathyametaanalysisofrandomizedcontrolledtrials |